FibroGen (NASDAQ:FGEN - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Monday, February 24th. Analysts expect FibroGen to post earnings of ($0.14) per share and revenue of $24.91 million for the quarter.
FibroGen Price Performance
NASDAQ:FGEN traded down $0.08 during midday trading on Tuesday, hitting $0.50. The company's stock had a trading volume of 4,303,142 shares, compared to its average volume of 4,883,456. FibroGen has a fifty-two week low of $0.18 and a fifty-two week high of $2.80. The firm has a market cap of $49.98 million, a P/E ratio of -0.40 and a beta of 0.75. The firm's 50 day moving average is $0.53 and its 200-day moving average is $0.43.
Analyst Ratings Changes
A number of analysts have recently weighed in on FGEN shares. StockNews.com initiated coverage on shares of FibroGen in a research note on Friday. They issued a "hold" rating on the stock. William Blair reiterated a "market perform" rating on shares of FibroGen in a research note on Wednesday, November 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of FibroGen in a report on Thursday, February 20th.
Check Out Our Latest Stock Report on FGEN
FibroGen Company Profile
(
Get Free Report)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Read More
Before you consider FibroGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroGen wasn't on the list.
While FibroGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
